Original Research

Published on 20 Sep 2022

The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study

in Thoracic Oncology

Hao-Ran Zheng
Ai-Min Jiang
Huan Gao
Na Liu
Xiao-Qiang Zheng
Xiao Fu
Zhi-Ping Ruan
Tao Tian
Xuan Liang
Yu Yao

Frontiers in Oncology

doi 10.3389/fonc.2022.894835

2,484 views
4 citations

Original Research

Published on 20 Sep 2022

Development and validation of a screening model for lung cancer using machine learning: A large-scale, multi-center study of biomarkers in breath

in Thoracic Oncology

Jing Li
Yuwei Zhang
Qing Chen
Zhenhua Pan
Jun Chen
Meixiu Sun
Junfeng Wang
Yingxin Li
Qing Ye

Frontiers in Oncology

doi 10.3389/fonc.2022.975563

2,401 views
5 citations

Original Research

Published on 20 Sep 2022

Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms

in Thoracic Oncology

Man Liu
Wanming Hu
Yixuan Zhang
Ning Zhang
Luohai Chen
Yuan Lin
Yu Wang
Yanji Luo
Yu Guo
Minhu Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.917743

2,113 views
2 citations

Systematic Review

Published on 20 Sep 2022

Chinese herbal injections versus intrapleural cisplatin for lung cancer patients with malignant pleural effusion: A Bayesian network meta-analysis of randomized controlled trials

in Thoracic Oncology

Yi-Fang Xu
Yun-Ru Chen
Fan-Long Bu
Yu-Bei Huang
Yu-Xin Sun
Cheng-Yin Li
Jodi Sellick
Jian-Ping Liu
Dan-Mei Qin
Zhao-Lan Liu

Frontiers in Oncology

doi 10.3389/fonc.2022.942941

3,489 views
5 citations

Original Research

Published on 20 Sep 2022

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

in Thoracic Oncology

Waleed Kian
Petros Christopoulos
Areen A. Remilah
Esther Levison
Elizabeth Dudnik
Walid Shalata
Bilal Krayim
Ranin Marei
Alexander Yakobson
Martin Faehling

Frontiers in Oncology

doi 10.3389/fonc.2022.1010311

6,685 views
8 citations

Original Research

Published on 16 Sep 2022

Propensity score-matched comparison of robotic- and video-assisted thoracoscopic surgery, and open lobectomy for non-small cell lung cancer patients aged 75 years or older

in Thoracic Oncology

Hanbo Pan
Zenan Gu
Yu Tian
Long Jiang
Hongda Zhu
Junwei Ning
Jia Huang
Qingquan Luo

Frontiers in Oncology

doi 10.3389/fonc.2022.1009298

2,656 views
19 citations

Original Research

Published on 16 Sep 2022

The value of narrow-band imaging bronchoscopy in diagnosing central lung cancer

in Thoracic Oncology

Juanjuan Zhu
Rui Liu
Xiancheng Wu
Qin Li
Beilei Gong
Yuanbing Shen
Yurong Ou
Wei Li

Frontiers in Oncology

doi 10.3389/fonc.2022.998770

2,680 views
4 citations

Editorial

Published on 16 Sep 2022

Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways

in Thoracic Oncology

Giannis Mountzios
Giuseppe Luigi Banna
Christian Rolfo

Frontiers in Oncology

doi 10.3389/fonc.2022.997404

1,889 views
1 citation

Original Research

Published on 15 Sep 2022

Expression and clinical significance of CD31, CD34, and CD105 in pulmonary ground glass nodules with different vascular manifestations on CT

in Thoracic Oncology

Chen-ran Guo
Rui Han
Feng Xue
Lin Xu
Wan-gang Ren
Meng Li
Zhen Feng
Ben-chuang Hu
Zhong-min Peng

Frontiers in Oncology

doi 10.3389/fonc.2022.956451

5,361 views
10 citations

Original Research

Published on 15 Sep 2022

Establishment and validation of a radiological-radiomics model for predicting high-grade patterns of lung adenocarcinoma less than or equal to 3 cm

in Thoracic Oncology

Hao Dong
Lekang Yin
Lei Chen
Qingle Wang
Xianpan Pan
Yang Li
Xiaodan Ye
Mengsu Zeng

Frontiers in Oncology

doi 10.3389/fonc.2022.964322

1,714 views
8 citations

Original Research

Published on 15 Sep 2022

CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma

in Thoracic Oncology

Jianlong Tan
Fengyu Chen
Bin Ouyang
Xiuying Li
Weidong Zhang
Xinglin Gao

Frontiers in Oncology

doi 10.3389/fonc.2022.865756

2,345 views
6 citations

Original Research

Published on 15 Sep 2022

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer

in Thoracic Oncology

Rebekah Rittberg
Bonnie Leung
Zamzam Al-Hashami
Cheryl Ho

Frontiers in Oncology

doi 10.3389/fonc.2022.1002385

3,487 views
5 citations

Original Research

Published on 14 Sep 2022

Clinical features and surgical outcomes of young patients with lung adenocarcinoma manifesting as ground glass opacity

in Thoracic Oncology

Rirong Qu
Dehao Tu
Yixin Cai
Wei Ping
Xiangning Fu

Frontiers in Oncology

doi 10.3389/fonc.2022.979522

1,586 views
4 citations

Original Research

Published on 14 Sep 2022

PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach

in Thoracic Oncology

Antonella Fameli
Valerio Nardone
Mojtaba Shekarkar Azgomi
Giovanna Bianco
Claudia Gandolfo
Bianca Maria Oliva
Marika Monoriti
Rita Emilena Saladino
Antonella Falzea
Caterina Romeo

Frontiers in Oncology

doi 10.3389/fonc.2022.911579

3,620 views
3 citations

Original Research

Published on 14 Sep 2022

Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung

in Thoracic Oncology

Hongbiao Wang
Jun Liu
Sujuan Zhu
Kun Miao
Zhifeng Li
Xiaofang Qi
Lujia Huang
Lijie Guo
Yan Wang
Yuyin Cai

Frontiers in Oncology

doi 10.3389/fonc.2022.945843

4,054 views
8 citations

Original Research

Published on 14 Sep 2022

Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors

in Thoracic Oncology

Richard Benjamin Young
Hemali Panchal
Weijie Ma
Shuai Chen
Aaron Steele
Andrea Iannucci
Tianhong Li

Frontiers in Oncology

doi 10.3389/fonc.2022.980181

1,482 views

Navigation group

Articles

The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study

Development and validation of a screening model for lung cancer using machine learning: A large-scale, multi-center study of biomarkers in breath

Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms

Chinese herbal injections versus intrapleural cisplatin for lung cancer patients with malignant pleural effusion: A Bayesian network meta-analysis of randomized controlled trials

Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer

Propensity score-matched comparison of robotic- and video-assisted thoracoscopic surgery, and open lobectomy for non-small cell lung cancer patients aged 75 years or older

The value of narrow-band imaging bronchoscopy in diagnosing central lung cancer

Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways

Expression and clinical significance of CD31, CD34, and CD105 in pulmonary ground glass nodules with different vascular manifestations on CT

Establishment and validation of a radiological-radiomics model for predicting high-grade patterns of lung adenocarcinoma less than or equal to 3 cm

CDCA4 as a novel molecular biomarker of poor prognosis in patients with lung adenocarcinoma

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer

Clinical features and surgical outcomes of young patients with lung adenocarcinoma manifesting as ground glass opacity

PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach

Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lung

Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors